Implications of overviews of randomized trials
- 1 April 1987
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 6 (3) , 397-402
- https://doi.org/10.1002/sim.4780060337
Abstract
Many randomized trials are of insufficient sample size to detect with adequate power the small to moderate effects that are most likely to occur. As a result, a single such trial can produce a null rinding that is, in fact, uninformative, but none the less is misinterpreted as demonstrating no effect. An overview considers all available trials and can increase the statistical power to detect an effect if present. Thus overviews can provide perhaps the most precise estimate of the magnitude of a treatment effect based on existing data. This may have implications for the formulation of public policy but certainly should influence the conduct and planning of randomized trials. Public policy may be influenced in circumstances where further trials are unlikely to be conducted. Overviews can also provide guidance as to whether changes in protocols of ongoing studies are recommended as a result of new evidence. Perhaps most importantly, overviews can provide information about whether additional trials are warranted, and, if so, the sample size that would be required to answer the research question definitively.Keywords
This publication has 12 references indexed in Scilit:
- Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trialsEuropean Heart Journal, 1985
- Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trialEuropean Heart Journal, 1985
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985
- Thrombolytic TherapyNew England Journal of Medicine, 1984
- EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1981
- Trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction.BMJ, 1981
- Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.Circulation, 1980
- A Randomized, Controlled Trial of Aspirin in Persons Recovered From Myocardial InfarctionJAMA, 1980
- ASPIRIN AND SECONDARY MORTALITY AFTER MYOCARDIAL INFARCTIONThe Lancet, 1979
- Aspirin in coronary heart diseaseJournal of Chronic Diseases, 1976